logo-loader
viewBiofrontera

Biofrontera confident ahead of FDA meeting on Ameluz

drug_research_350_53f5f07e66472.jpg

Biofrontera (LON:B8F) has a meeting scheduled with the US Food and Drug Administration (FDA) ahead of its filing key products Ameluz and BF-RhodoLED for approval.

The pre-NDA (new drug application) meeting, set for 8 October, represents the last opportunity to obtain direct feedback from the US regulator prior to the application.

Ameluz is a prescription drug approved in Europe for the treatment of mild to moderate actinic keratosis. BF-RhodoLED is a CE-marked red light LED lamp used in combination with Ameluz in photodynamic therapy (PDT).  Both products are already sold in most major European markets.

After the FDA requested additional studies in 2012, Biofrontera has performed two phase I trials and one phase III study, results of which are due at the end of September or early October.

A  Briefing Book has been submitted to the FDA to serve as a guide to introduce all major elements of the dossier as well as discuss remaining questions.

Hermann Luebbert, Biofrontera’s chief executive, said: "We are looking forward to the opportunity to discuss our dossier for the combination of Ameluz and BF-RhodoLED with the FDA.

“We are confident that our data package will now satisfy all the requirements for filing.

“Whilst we had hoped for an earlier meeting, this delay will not influence the rest of our time table of filing the final dossier by the end of Q1 2015."

Earlier today, Biofriontera also revealed it was taking legal action against a former supplier, Biosynth, which used to produce one of the main ingredients used in Ameluz.

Shares rose 4% to 232p.

Quick facts: Biofrontera

Price: - -

AIM:B8F
Market: AIM
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

W Resources chairman at La Parrilla to update on grant funding and new loan

W Resources PLC's (LON:WRES) chairman Michael Masterman gives a progress report on developments at both its flagship project La Parrilla in Spain and Régua in northern Portugal. This week WRES announced its put in place a €5mln facility with Banco Santander. It's to allow them to monetise the...

3 hours, 30 minutes ago

2 min read